SC
ORIC icon

SummitTX Capital’s Oric Pharmaceuticals ORIC Stock Holding History

SummitTX Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538K Buy
+42,446
New +$482K 0.02% 555

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SummitTX Capital's ORIC Position: Q1 2026 in Review

SummitTX Capital opened a new position in Oric Pharmaceuticals (ORIC) in Q1 2026: 42,446 shares worth $538K. The stake represents 0.02% of the portfolio and ranks #555 among its holdings.

182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • SummitTX Capital held 42,446 shares of Oric Pharmaceuticals worth $538K as of Q1 2026.
  • Oric Pharmaceuticals was a new SummitTX Capital position in Q1 2026.
  • Oric Pharmaceuticals made up 0.02% of SummitTX Capital's portfolio in Q1 2026, its #555 holding.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.